{rfName}
Cl

Indexed in

License and use

Citations

27

Altmetrics

Analysis of institutional authors

Salas MqAuthorDomingodomènech EAuthorMercadal SAuthorFernandez De Sevilla AAuthorSureda AAuthorSancho JmAuthorGonzalez-Barca ECorresponding Author

Share

November 25, 2019
Publications
>
Article
No

Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution.

Publicated to:Biomarkers. 25 (1): 1-7 - 2020-01-02 25(1), DOI: 10.1080/1354750X.2019.1691656

Authors: Salas MQ, Climent F, Tapia G, DomingoDomènech E, Mercadal S, Oliveira AC, Aguilera C, Olga G, Moreno Velázquez M, Andrade-Campos M, Encuentra M, Fernández de Sevilla A, Sureda A, Sancho JM, González-Barca E

Affiliations

Cancer. Molecular Mechanisms and Experimental Therapy in Oncology Program. Hematopoyetic and lymphoid tumors - Author
Cancer. Molecular Mechanisms and Experimental Therapy in Oncology Program. Neuro-Oncology Unit - Author
Hosp Badalona Germans Trias & Pujol, ICO, Dept Clin Haematol, IJC, Badalona, Spain - Author
Inst Catal Oncol ICO Hospitalet, Dept Clin Haematol, IDIBELL, Ave Gran Via 199-203, Barcelona 08908, Spain - Author
Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, Dept Pathol, Barcelona, Spain - Author
Univ Hosp Bellvitge, Dept Pathol, Barcelona, Spain - Author
See more

Abstract

Introduction: The present study evaluates CD30 expression by immunohistochemistry (IHQ) in 216 patients with de novo DLBCL.Methods: CD30 expression was assessed retrospectively in all cases by IHQ. More than >0% and >20% of CD30 expression in the malignant cells were used as a cut-off for positivity. Survival was analysed in 176 patients treated with R-CHOP/R-CHOP-like regimens.Results: CD30 expression >0% was found in 66 (31%) patients, and >20% in 41 (19%). Younger patients <60?years (p?=?0.03), good performance status (p?=?0.04), and non-GCB subtype (p?=?0.004) correlated with CD30 expression. No significant differences were found in overall survival and progression-free survival (PFS), although there was a trend towards better PFS in CD30-positive patients (p?=?0.07). Among 7 patients with Epstein-Barr virus (EBV)-positive-DLBCL, CD30 was expressed in 71%, and 2-year PFS significantly inferior compared with CD30-positive EBV-negative-DLBCL patients (p?=?0.01).Conclusion: CD30 is expressed in 30% of DLBCL patients, in whom targeted therapy with an anti-CD30 monoclonal antibody could be explored. CD30 is expressed more frequently younger patients, with better performance status and in the non-GCB subtype and its expression trends towards a better PFS. No significant differences regarding characteristics at diagnosis or prognosis were found between groups with different cut-off for positivity.

Keywords

AdultAgeAgedAged, 80 and overAntigen expressionAntineoplastic agentAntineoplastic combined chemotherapy protocolsArticleBiomarkers, tumorCancer cellCancer prognosisCancer recurrenceCancer survivalCd30Cell of originClinical featureClinical outcomeCyclophosphamideCyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristineDiffuse large b cell lymphomaDiffuse large b-cell lymphomaDoxorubicinEpstein barr virusFemaleHistopathologyHumanHuman cellHuman tissueHumansImmunohistochemistryImmunologyKi-1 antigenLymphoma, large b-cell, diffuseMajor clinical studyMaleMiddle agedMolecularly targeted therapyMonoclonal antibodyMortalityNonhumanOverall survivalPathologyPredictive valuePredictive value of testsPrednisonePrognostic factorProgression free survivalProgression-free survivalR-chop protocolRetrospective studiesRetrospective studyRituximabSurvivalSurvival analysisTreatment responseTumor markerTumor necrosis factor receptor superfamily member 8Very elderlyVincristineYoung adult

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Biomarkers due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2020, it was in position , thus managing to position itself as a Q2 (Segundo Cuartil), in the category Medicine (Miscellaneous). Notably, the journal is positioned en el Cuartil Q3 for the agency WoS (JCR) in the category Biotechnology & Applied Microbiology.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 4.31, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-16, the following number of citations:

  • WoS: 4
  • Scopus: 16
  • Europe PMC: 6

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-16:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 22.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 23 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 0.75.
  • The number of mentions on the social network X (formerly Twitter): 2 (Altmetric).

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Salas Gay, Queralt) and Last Author (Gonzalez Barca, Eva Maria).

the author responsible for correspondence tasks has been Gonzalez Barca, Eva Maria.